AiRuiKa (camrelizumab)

In the treatment of locally advanced NPC, a randomized phase III study showed equivalence of induction (ICT) and adjuvant therapy (AT; NCT03306121). PD-1 inhibitors have become established in the palliative therapy of NPC in recent years and could now also play an increasing role in curation: the phase III study "Dipper" showed a significantly better 3‑year event-free survival in patients adjuvantly treated with camrelizumab versus placebo after IT and definitive platinum-containing chemoradiotherapy (dRCT; 89% vs. 80%; NCT03427827). The phase III study "Beacon" showed complete remission in 30.5% of patients after IT with gemcitabine/cisplatin and the PD‑1 inhibitor tislelizumab (three cycles), a rate almost twice as high as with gemcitabine/cisplatin alone (NCT05211232). Intensification of dRCT in NPC using EGFR and VEGF inhibitors appears promising (NCT04447326). Abstracts on salivary gland and nasal and sinus cancers emphasize the importance of targeted therapies. In anaplastic thyroid carcinoma, the combination of a PD‑1 inhibitor and a CTLA4 inhibitor showed a 50% response.

P1, N=6, Recruiting, West China Hospital | Trial primary completion date: Oct 2024 --> Oct 2025

P=N/A, N=14, Recruiting, Fudan University | Not yet recruiting --> Recruiting

Firstly, we describe the patient's treatment history, including failed third-line combination treatments of systemic chemotherapy with bevacizumab or carrelizumab or anlotinib, primary lung tumor recurrence, bilateral lung metastases progression, and new brain metastatic lesion detection. Next, we detail the patient's fourth-line treatment with radiotherapy for brain metastases and two cycles of bevacizumab plus Abraxane and cisplatin, however, the disease progressed and relapsed...However, the patient died due to hypoproteinemia combined with severe pneumonia in December 2023. Furmonertinib may be effective for NSCLC patients with HER2 T8962A and L869R mutations and further studies are needed to confirm these results in prospective clinical trials.

P=N/A, N=75, Not yet recruiting, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine; Shanghai First Maternity and Infant Hospital, Tongji University Sc

P4, N=128, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University

P2, N=33, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P3, N=885, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed

P2, N=39, Completed, Nanfang Hospital, Southern Medical University | Recruiting --> Completed

P3, N=586, Recruiting, Sun Yat-sen University

P2, N=40, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting

The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n = 4, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.

P2, N=58, Terminated, Huazhong University of Science and Technology | Trial completion date: Jun 2023 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2023 --> Nov 2023; slow recruitment forcing early suspension of screening and enrollment

P3, N=242, Not yet recruiting, Sun Yat-sen University

P2, N=85, Active, not recruiting, Huazhong University of Science and Technology | Recruiting --> Active, not recruiting

BMI is a long-term predictor of the efficacy of lenvatinib plus camrelizumab, and obese/overweight patients have a better prognosis.

P2/3, N=440, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting

P2, N=40, Recruiting, Tongji Hospital | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Sep 2024

P1, N=6, Recruiting, West China Hospital

Our findings identify CD34 as a novel spatial biomarker for anti-PD-1 therapy efficacy, potentially guiding the selection of aNSCLC patients who are more likely to benefit from ICI treatment. ChiCTR2000040416.

P2, N=3, Terminated, Beijing Sanbo Brain Hospital | N=94 --> 3 | Suspended --> Terminated; Lack of funds

P2, N=21, Recruiting, Beijing Sanbo Brain Hospital | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=34, Suspended, Zhejiang Cancer Hospital | Recruiting --> Suspended

Combination kinase inhibitors with immunotherapy as first-line therapy are safe and effective for the treatment of unresectable ATC, especially with BRAF V600E mutation.

P=N/A, N=14, Not yet recruiting, Fudan University

P2, N=46, Not yet recruiting, Beijing Tsinghua Chang Gung Hospital

P2, N=60, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

P=N/A, N=84, Recruiting, First Hospital of China Medical University

P=N/A, N=97, Active, not recruiting, First Hospital of China Medical University

P=N/A, N=228, Recruiting, First Hospital of China Medical University

P2, N=620, Recruiting, Fudan University | N=140 --> 620

P=N/A, N=42, Recruiting, Sun Yat-sen University

Changes in SUVmax (AUC, 0.81; P = 0.0116), SUVpeak (AUC, 0.82; P = 0.0097), SUVmean (AUC, 0.81; P = 0.0116), and TBRmean (AUC, 0.74; P = 0.0489) also were significant predictors of the pathologic response to nCC, with sensitivities and specificities in similar ranges. 18F-FAPI PET/CT parameters after treatment and their changes from baseline can predict the pathologic response to nCC in LA-ESCC participants.

P2, N=41, Not yet recruiting, Zhejiang Cancer Hospital

P=N/A, N=43, Recruiting, The First Affiliated Hospital of Soochow University | Trial primary completion date: Jul 2024 --> Jul 2025

P2, N=29, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Camrelizumab combining chemotherapy significantly prolonged the mPFS and mOS of advanced BTC patients. Immunotherapy may improve the immune status of advanced patients, and immunotherapy efficacy might be predicted based on the peripheral blood lymphocyte subsets.

P=N/A, N=90, Not yet recruiting, Ying Zhang

Camrelizumab and chemotherapy were administered, and the metastasis disappeared. Immunotherapy combined with platinum-based chemotherapy is effective in treating PSC with pancreatic metastases.

P=N/A, N=38, Not yet recruiting, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University

P=N/A, N=30, Recruiting, First affiliated hospital of Soochow university; First affiliated hospital of Soochow university

P4, N=41, Not yet recruiting, Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College